Yao, D., Hill, N., Brown, B., Gule, D., Chabane, M., Mcingana, M., Willis, K., Shiba, V., Olawore, O., Nel, D. and Pienaar, J., 2024. The impact of COVID-19 restrictions on HIV prevention and treatment services for key populations in South Africa: an interrupted time series analysis. BMC Public Health, 24(1), p.2386.
Fritschi, N., Gureva, T., Eliseev, P., Jackson, C., Milanzi, E., Crichton, S., Collins, I.J., Turkova, A., Mariandyshev, A. and Ritz, N., 2024. Diagnosis of tuberculosis infection in children with a novel skin test and the traditional tuberculin skin test: An observational study. PloS one, 19(8), p.e0293272.
White, R.G., Fiore-Gartland, A.J., Hanekom, W.A., Vekemans, J., Garcia-Basteiro, A.L., Churchyard, G., Rangaka, M.X., Frick, M., Behr, M.A., Hill, P.C. and Mave, V., 2024. What is next for BCG revaccination to prevent tuberculosis?. The Lancet Respiratory Medicine.
Fwambah, L., Andisi, C., Streatfield, C., Bromell, R., Hare, J., Esbjörnsson, J., Ndung’u, T., Sanders, E.J., Hassan, A.S. and Nduati, E., 2023. Exposure to common infections may shape basal immunity and potentially HIV-1 acquisition amongst a high-risk population in Coastal Kenya. Frontiers in Immunology, 14.
Mabuto, T., Woznica, D.M., Ndini, P., Moyo, D., Abraham, M., Hanrahan, C., Charalambous, S., Zack, B., Baral, S., Owczarzak, J. and Hoffmann, C.J., 2024. Transitional community adherence support for people leaving incarceration in South Africa: a pragmatic, open-label, randomised controlled trial. The Lancet HIV, 11(1), pp.e11-e19.
Reid, M., Agbassi, Y.J.P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D. and Churchyard, G., 2023. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis. The Lancet.
Dierig, A., Hoelscher, M., Schultz, S., Hoffmann, L., Jarchow-MacDonald, A., Svensson, E.M., Te Brake, L., Aarnoutse, R., Boeree, M., McHugh, T.D. and Wildner, L.M., 2023. A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis. Trials, 24(1), pp.1-15.
Krause, R., Warren, C.M., Simmons, J.D., Rebeiro, P.F., Maruri, F., Karim, F., Sterling, T.R., Koethe, J.R., Leslie, A. and van der Heijden, Y.F., 2023. Failure to decrease HbA1c levels following TB treatment is associated with elevated Th1/Th17 CD4+ responses. Frontiers in Immunology, 14, p.1151528.
